Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Oncology

Advertisement

Advertisement

Featured

Bradley Corr, MD
Conference Coverage
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology
John Allan, MD
Conference Coverage
03/20/2024

Featuring John Allan, MD

Featuring John Allan, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, John Allan, MD, discusses novel updates in the chronic lymphocytic leukemia treatment landscape, highlighting studies that focused on BTK inhibitor combination treatments.
At the Lymphoma, Leukemia & Myeloma Congress in New York, John Allan, MD, discusses novel updates in the chronic lymphocytic leukemia treatment landscape, highlighting studies that focused on BTK inhibitor combination treatments.
At the Lymphoma, Leukemia &...
03/20/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network
Brian M. Slomovitz, MD
Conference Coverage
03/18/2024

Featuring Brian M. Slomovitz, MD

Featuring Brian M. Slomovitz, MD ...
At the SGO 2024 Annual Meeting, Brian M. Slomovitz, MD, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial which found tisotumab vedotin significantly improved survival outcomes among patients with second-/third-line recurrent...
At the SGO 2024 Annual Meeting, Brian M. Slomovitz, MD, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial which found tisotumab vedotin significantly improved survival outcomes among patients with second-/third-line recurrent...
At the SGO 2024 Annual Meeting,...
03/18/2024
Oncology
David Cibula, MD, PhD
Conference Coverage
03/17/2024

Featuring David Cibula, MD, PhD

Featuring David Cibula, MD, PhD ...
At the SGO 2024 Annual Meeting, David Cibula, MD, PhD, discussed results from the CEEGOG CX-01, ENGOT-CX2 trial which identified sentinel lymph node biopsy plus pathologic ultrastaging as safe and effective for patients with early-stage...
At the SGO 2024 Annual Meeting, David Cibula, MD, PhD, discussed results from the CEEGOG CX-01, ENGOT-CX2 trial which identified sentinel lymph node biopsy plus pathologic ultrastaging as safe and effective for patients with early-stage...
At the SGO 2024 Annual Meeting,...
03/17/2024
Oncology
Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center
Videos
03/12/2024

Featuring Andrew Zelenetz, MD

Featuring Andrew Zelenetz, MD
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses...
03/12/2024
Oncology
Jennifer Amengual, MD, Columbia University
Conference Coverage
03/11/2024

Featuring Jennifer Amengual, MD

Featuring Jennifer Amengual, MD ...
At the Lymphoma, Leukemia & Myeloma Congress in New York, Jennifer Amengual, MD, discusses new approvals and treatment strategies for older patients with aggressive lymphoma who are ineligible for CAR T-cell therapy.
At the Lymphoma, Leukemia & Myeloma Congress in New York, Jennifer Amengual, MD, discusses new approvals and treatment strategies for older patients with aggressive lymphoma who are ineligible for CAR T-cell therapy.
At the Lymphoma, Leukemia &...
03/11/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network
Jennifer Amengual, MD, Columbia University
Conference Coverage
03/11/2024

Featuring Jennifer Amengual, MD

Featuring Jennifer Amengual, MD ...
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Jennifer Amengual, MD, discusses novel therapeutic targets for elderly patients with DLBCL who are not candidates for CAR T-cell therapy.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Jennifer Amengual, MD, discusses novel therapeutic targets for elderly patients with DLBCL who are not candidates for CAR T-cell therapy.
At the Lymphoma, Leukemia &...
03/11/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares...
03/07/2024
Oncology
Eytan M Stein, MD
Q&As
03/07/2024

Featuring Eytan M Stein, MD

Featuring Eytan M Stein, MD
Eytan M Stein, MD, shares expert insights on preventing transformation and reducing the symptom burden of adverse events among patients with myelofibrosis.
Eytan M Stein, MD, shares expert insights on preventing transformation and reducing the symptom burden of adverse events among patients with myelofibrosis.
Eytan M Stein, MD, shares expert...
03/07/2024
Oncology
Eytan M Stein, MD
Q&As
03/07/2024

Featuring Eytan M Stein, MD

Featuring Eytan M Stein, MD
Eytan M Stein, MD, discusses findings from the MANIFEST trial which evaluated the efficacy and safety of pelabresib among patients with acute leukemia, high-risk myelodysplastic syndrome, or MDS/MPN.
Eytan M Stein, MD, discusses findings from the MANIFEST trial which evaluated the efficacy and safety of pelabresib among patients with acute leukemia, high-risk myelodysplastic syndrome, or MDS/MPN.
Eytan M Stein, MD, discusses...
03/07/2024
Oncology
Jia Ruan, MD, PhD
Conference Coverage
03/01/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses the introduction of chemotherapy-free novel agents for the treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses the introduction of chemotherapy-free novel agents for the treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia &...
03/01/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network

Advertisement

Advertisement

Advertisement

Insights From the ESMO Congress

Conference Coverage
11/22/2023

Stephanie Holland 

Stephanie Holland 
Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.
Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.
Biomarker analyses from patients...
11/22/2023
Oncology
Juergen C. Becker, MD, PhD
Conference Coverage
11/20/2023

Featuring Juergen C. Becker, MD, PhD

Featuring Juergen C. Becker, MD, PhD ...
Juergen C. Becker, MD, PhD, German Cancer Consortium, discusses preliminary findings from the phase 2 AliCe study combining avelumab with cetuximab for patients with advanced, unresectable cutaneous squamous cell carcinoma.
Juergen C. Becker, MD, PhD, German Cancer Consortium, discusses preliminary findings from the phase 2 AliCe study combining avelumab with cetuximab for patients with advanced, unresectable cutaneous squamous cell carcinoma.
Juergen C. Becker, MD, PhD,...
11/20/2023
Oncology
Arlene Siefker-Radtke, MD, MD Anderson Cancer Center
Videos
11/16/2023

Featuring Arlene Seifker-Radtke, MD

Featuring Arlene Seifker-Radtke, MD ...
Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.
Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.
Arlene Siefker-Radtke, MD,...
11/16/2023
Oncology
Sara Lonardi, MD, Veneto Institute of Oncology
Videos
11/16/2023

Featuring Sara Lonardi, MD

Featuring Sara Lonardi, MD
Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.
Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.
Sara Lonardi, MD, shares results...
11/16/2023
Oncology
Kohei Shitara, MD, PhD, National Cancer Center Hospital East
Videos
11/14/2023

Featuring Kohei Shitara, MD, PhD

Featuring Kohei Shitara, MD, PhD ...
In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.
In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.
In the KEYNOTE-585 study,...
11/14/2023
Oncology
Quiz
11/13/2023
Allison Casey
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the...
11/13/2023
Oncology
Oleg Gluz, MD
Conference Coverage
11/10/2023

Featuring Oleg Gluz, MD

Featuring Oleg Gluz, MD
Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.
Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.
Oleg Gluz, MD, Evangelical...
11/10/2023
Oncology
News
11/10/2023
Allison Casey
Results from the phase 3 RADICALS-RT trial found there was no meaningful benefit derived from adjuvant radiotherapy following radical prostatectomy for patients with prostate cancer.
Results from the phase 3 RADICALS-RT trial found there was no meaningful benefit derived from adjuvant radiotherapy following radical prostatectomy for patients with prostate cancer.
Results from the phase 3...
11/10/2023
Oncology
News
11/10/2023
Allison Casey
Niraparib plus abiraterone acetate and prednisone improved several outcomes measures, including overall survival, among patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Niraparib plus abiraterone acetate and prednisone improved several outcomes measures, including overall survival, among patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Niraparib plus abiraterone...
11/10/2023
Oncology

Insights From the ASCO Annual Meeting

Stefan Knop, MD
Videos
08/28/2023

Featuring Stefan Knop, MD

Featuring Stefan Knop, MD
Stefan Knop, MD, presents initial results from a randomized phase 3 study of triplet vs quadruplet therapeutic regimen for patients with newly diagnosed transplant-eligible multiple myeloma.
Stefan Knop, MD, presents initial results from a randomized phase 3 study of triplet vs quadruplet therapeutic regimen for patients with newly diagnosed transplant-eligible multiple myeloma.
Stefan Knop, MD, presents...
08/28/2023
Oncology
Kathleen Moore, MD, Stephenson Cancer Center
Videos
07/27/2023
At the 2023 ASCO Annual Meeting, Kathleen Moore, MD, shares results from the MIRASOL trial, evaluating mirvetuximab soravtansine among patients with folate recetor alpha-high platinum-resistant ovarian cancer.
At the 2023 ASCO Annual Meeting, Kathleen Moore, MD, shares results from the MIRASOL trial, evaluating mirvetuximab soravtansine among patients with folate recetor alpha-high platinum-resistant ovarian cancer.
At the 2023 ASCO Annual Meeting,...
07/27/2023
Oncology
Reid Merryman, MD
Videos
07/19/2023

Featuring Reid Merryman, MD

Featuring Reid Merryman, MD
At the 2023 ASCO meeting, Reid Merryman, MD, shares data assessing the efficacy and safety of epcoritamab plus rituximab and lenalidomide among patients with R/R FL.
At the 2023 ASCO meeting, Reid Merryman, MD, shares data assessing the efficacy and safety of epcoritamab plus rituximab and lenalidomide among patients with R/R FL.
At the 2023 ASCO meeting, Reid...
07/19/2023
Oncology
Conference Coverage
07/18/2023

Amber Denham

Amber Denham
The addition of sintilimab to standard induction chemotherapy and concurrent chemoradiotherapy resulted in improved event-free survival in high-risk LANPC.
The addition of sintilimab to standard induction chemotherapy and concurrent chemoradiotherapy resulted in improved event-free survival in high-risk LANPC.
The addition of sintilimab to...
07/18/2023
Oncology
Tsz Lun Yeung, MD
Videos
07/18/2023

Featuring Tsz Lun Yeung, MD

Featuring Tsz Lun Yeung, MD
At the 2023 ASCO Annual Meeting, Tsz Lun Yeung, MD, presented data which found extended dosing with the IAP inhibitor xevanipant improved the efficacy of radiotherapy in preclinical models of head and neck squamous cell carcinoma.
At the 2023 ASCO Annual Meeting, Tsz Lun Yeung, MD, presented data which found extended dosing with the IAP inhibitor xevanipant improved the efficacy of radiotherapy in preclinical models of head and neck squamous cell carcinoma.
At the 2023 ASCO Annual Meeting,...
07/18/2023
Oncology
Paul Paik, MD, Memorial Sloan Kettering Cancer Center
Videos
07/17/2023

Featuring Paul Paik, MD

Featuring Paul Paik, MD
At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.
At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.
At the 2023 ASCO Annual Meeting,...
07/17/2023
Oncology
Ticiana Leal, MD, Winship Cancer Institute
Videos
07/17/2023

Featuring Ticiana Leal, MD 

Featuring Ticiana Leal, MD 
At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...
At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...
At the 2023 ASCO Annual Meeting,...
07/17/2023
Oncology
Tycel Phillips, MD
Videos
06/26/2023

Featuring Tycel Phillips, MD

Featuring Tycel Phillips, MD
Tycel Phillips, MD, presented data at the 2023 ASCO annual meeting on the safety and efficacy of acalabrutinib in combination with bendamustine and rituximab among patients with treatment-naive or R/R mantle cell lymphoma.
Tycel Phillips, MD, presented data at the 2023 ASCO annual meeting on the safety and efficacy of acalabrutinib in combination with bendamustine and rituximab among patients with treatment-naive or R/R mantle cell lymphoma.
Tycel Phillips, MD, presented...
06/26/2023
Oncology
Carlotta Antoniotti, MD, PhD, University of Pisa
Videos
06/22/2023

Featuring Carlotta Antoniotti, MD, PhD

Featuring Carlotta Antoniotti, MD, Ph...
At the 2023 ASCO annual meeting, Carlotta Antoniotti, MD, PhD, shares data from the AtezoTRIBE study evaluating the addition of atezolizumab to FOLFOXIRI plus bevacizumab for metastatic colorectal cancer.
At the 2023 ASCO annual meeting, Carlotta Antoniotti, MD, PhD, shares data from the AtezoTRIBE study evaluating the addition of atezolizumab to FOLFOXIRI plus bevacizumab for metastatic colorectal cancer.
At the 2023 ASCO annual meeting,...
06/22/2023
Oncology
Kerry Rogers, MD
Videos
06/22/2023

Featuring Kerry Anne Rogers, MD

Featuring Kerry Anne Rogers, MD ...
At the 2023 ASCO Annual Meeting in Chicago, Illinois, Kerry Anne Rogers, MD, provided insights into real-world dosing ibrutinib patterns and outcomes among patients with chronic lymphocytic leukemia.
At the 2023 ASCO Annual Meeting in Chicago, Illinois, Kerry Anne Rogers, MD, provided insights into real-world dosing ibrutinib patterns and outcomes among patients with chronic lymphocytic leukemia.
At the 2023 ASCO Annual Meeting...
06/22/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Live Meetings

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement